百利天恒拟申请注册发行不超100亿元债务融资工具

Core Viewpoint - Baili Tianheng plans to issue debt financing instruments with a total scale not exceeding RMB 10 billion, which may include various types of bonds such as medium-term notes and short-term financing bonds [2] Group 1: Debt Financing Instruments - The company intends to apply for the registration and issuance of debt financing tools, which may include but are not limited to medium-term notes, short-term financing bonds, and ultra-short-term financing bonds [2] - The expected issuance is aligned with the regulations of the China Interbank Market Dealers Association and is anticipated to be labeled as technology innovation bonds [2] Group 2: Fund Utilization - The funds raised from this bond issuance are planned to be used for research and development investments, repayment of interest-bearing debts, and supplementing working capital [2] - Additionally, the funds may be allocated for project equity investments and mergers and acquisitions that comply with legal regulations [2]

BIOKIN PHARMACEUTICAL-百利天恒拟申请注册发行不超100亿元债务融资工具 - Reportify